At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 121 enrolled
Drug / intervention
pembrolizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Pembrolizumab Monotherapy in Third Line Previously Treated Subjects With Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced/Metastatic Siewert Type I Adenocarcinoma of the Esophagogastric Junction (KEYNOTE-180)
In Brief
A Phase 2 clinical trial evaluating pembrolizumab for Esophageal Carcinoma and Esophagogastric Junction Carcinoma. Completed, enrolled 121 participants.
Detailed Summary
In this study participants with advanced/metastatic adenocarcinoma of the esophagus (EAC), squamous cell carcinoma of the esophagus (ESCC), or advanced/metastatic Siewert type I adenocarcinoma of the esophagogastric junction (EGJ), who had been previously treated with two standard therapies, will be treated with pembrolizumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartDec 2015
Primary CompletionJul 2018
Study CompletionOct 2021
TodayJul 2026
First PostedSep 24, 2015
Enrollment StartDec 2, 2015
Primary CompletionJul 30, 2018
Study CompletionOct 29, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 10.8 years ago
Interventions
pembrolizumabbiological
IV Q3W